ZA200406272B - Deazapurines and uses thereof - Google Patents

Deazapurines and uses thereof Download PDF

Info

Publication number
ZA200406272B
ZA200406272B ZA2004/06272A ZA200406272A ZA200406272B ZA 200406272 B ZA200406272 B ZA 200406272B ZA 2004/06272 A ZA2004/06272 A ZA 2004/06272A ZA 200406272 A ZA200406272 A ZA 200406272A ZA 200406272 B ZA200406272 B ZA 200406272B
Authority
ZA
South Africa
Prior art keywords
aryl
aliphatic
heteroaliphatic
compound
heteroaryl
Prior art date
Application number
ZA2004/06272A
Other languages
English (en)
Inventor
M Seletsky Boris
Zheng Wanjun
Kaneko Toshihiko
Kobayashi Seiichi
Hishinuma Ieharu
Soejima Motohiro
Daun Jane
A Davis Heather
Gusovsky Fabian
Jiang Yimin
Kikuchi Kouichi
LESCARBEAU Andrew
Li Xiang-Yi
Muramoto Kenzo
Ohi Norihito
Pesant Marc
Yao Ye
Yokohama Hiromitsu
Tremblay Lynda
F Decosta Bruce
Yan Zhao (Janet)
Mark Spyvee
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of ZA200406272B publication Critical patent/ZA200406272B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2004/06272A 2002-01-07 2004-08-05 Deazapurines and uses thereof ZA200406272B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34659802P 2002-01-07 2002-01-07
PCT/US2003/000366 WO2003057696A1 (en) 2002-01-07 2003-01-07 Deazapurines and uses thereof

Publications (1)

Publication Number Publication Date
ZA200406272B true ZA200406272B (en) 2006-01-25

Family

ID=23360154

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/06272A ZA200406272B (en) 2002-01-07 2004-08-05 Deazapurines and uses thereof

Country Status (22)

Country Link
US (4) US7314936B2 (https=)
EP (2) EP1474425B9 (https=)
JP (1) JP4411455B2 (https=)
KR (2) KR101108722B1 (https=)
CN (1) CN100503608C (https=)
AT (1) ATE327236T1 (https=)
AU (2) AU2003235741B8 (https=)
BR (1) BR0306785A (https=)
CA (1) CA2472479C (https=)
CY (1) CY1106138T1 (https=)
DE (2) DE60305446D1 (https=)
DK (1) DK1474425T3 (https=)
ES (1) ES2262996T3 (https=)
IL (3) IL162884A0 (https=)
MX (1) MXPA04006614A (https=)
NO (1) NO329994B1 (https=)
NZ (2) NZ533958A (https=)
PT (1) PT1474425E (https=)
RU (1) RU2380368C2 (https=)
SI (1) SI1474425T1 (https=)
WO (1) WO2003057696A1 (https=)
ZA (1) ZA200406272B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006083908A1 (en) * 2005-02-02 2006-08-10 Eisai Co., Ltd. Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2007125315A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
US8507473B2 (en) * 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
WO2012033149A1 (ja) 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
SG192941A1 (en) * 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EA027506B1 (ru) 2011-04-01 2017-08-31 Астразенека Аб Способ лечения рака молочной железы
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
BR112014001018A2 (pt) 2011-07-15 2017-01-10 Shionogi & Co derivado de azabenzimidazol tendo atividade de ativação de ampk
HRP20191982T4 (hr) 2011-11-30 2023-01-06 Astrazeneca Ab Kombinacijsko liječenje raka
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
GB201401198D0 (en) * 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN104974187A (zh) * 2014-04-10 2015-10-14 吉林省博创药业有限公司 菲罗啉类衍生物及其制备方法和应用
US10253023B2 (en) * 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7227157B2 (ja) 2016-12-29 2023-02-21 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
KR20190043437A (ko) * 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
BR112020011668A2 (pt) 2017-12-15 2020-11-17 Bristol-Myers Squibb Company compostos de éter de indol substituído
JP7313354B2 (ja) * 2017-12-19 2023-07-24 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物
BR112020012084A2 (pt) * 2017-12-19 2020-11-24 Bristol-Myers Squibb Company compostos de indol substituído úteis como inibidores de tlr
WO2019126082A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
BR112020011984A2 (pt) * 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos de amino indol úteis como inibidores de tlr
US11299501B2 (en) 2017-12-20 2022-04-12 Bristol-Myers Squibb Company Diazaindole compounds
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
EP3965888B1 (en) 2019-05-09 2024-08-21 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891660A (en) * 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4939146A (en) * 1987-01-29 1990-07-03 Kramer Richard S Method for alleviating ischemic-reperfusion injury
DE3702757A1 (de) 1987-01-30 1988-08-11 Hoechst Ag Neue imidazo- und triazolo-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte
US4999365A (en) * 1987-03-20 1991-03-12 Merrell Dow Pharmaceuticals Inc. Method of reducing reperfusion injury with imidazol-2-thiones
US4877810A (en) * 1988-02-05 1989-10-31 Eastman Kodak Company Protection of heart tissue from reperfusion injury
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5298518A (en) 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5081253A (en) 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
WO1994000451A1 (de) 1992-06-22 1994-01-06 Boehringer Ingelheim Kg 9-AMINO-PYRIDAZINO[4',5' : 3,4]PYRROLO-[2,1-a]ISOCHINOLINE UND DEREN VERWENDUNG FÜR DIE HERSTELLUNG VON PHARMAZEUTISCHEN ZUBEREITUNGEN
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
US5360794A (en) 1992-08-03 1994-11-01 Medicarb Inc. Disubstituted and deoxy disubstituted derivatives of α-D-mannofuranosides and β-L-gulofuranosides having anti-inflammatory and anti-proliferative activity
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
IL123431A (en) * 1995-11-22 2001-05-20 Darwin Discovery Ltd Mercaptoalkyl peptidil compounds with imidazole transducer and their use as metallic protonase matrix (MMP) compounds and / or tumor cause factor (TNF)
US5981536A (en) 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
JPH10139709A (ja) 1996-11-13 1998-05-26 Chisso Corp フェニルポリハロアルキルエーテル誘導体、これを含む液晶組成物および液晶表示素子
ATE240949T1 (de) * 1997-04-18 2003-06-15 Taiho Pharmaceutical Co Ltd Epoxysuccinamid-derivate oder ihre salze
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
EA002973B1 (ru) 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
DK1194425T3 (da) * 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
AU7922900A (en) * 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
CA2399136A1 (en) 2000-02-09 2001-08-16 Hideo Kato 1h-imidazopyridine derivatives
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002092573A2 (en) * 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
HUP0402344A2 (hu) * 2001-12-04 2005-02-28 F. Hoffmann-La Roche Ag Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
US6861278B2 (en) * 2002-04-11 2005-03-01 Nordson Corporation Method and apparatus for underfilling semiconductor devices
WO2006083908A1 (en) * 2005-02-02 2006-08-10 Eisai Co., Ltd. Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses

Also Published As

Publication number Publication date
EP1474425B9 (en) 2008-07-02
BR0306785A (pt) 2004-11-09
US20050124649A1 (en) 2005-06-09
IL197484A0 (en) 2009-12-24
WO2003057696A1 (en) 2003-07-17
IL191543A0 (en) 2008-11-03
KR20100066593A (ko) 2010-06-17
US7868002B2 (en) 2011-01-11
ATE327236T1 (de) 2006-06-15
KR101108722B1 (ko) 2012-02-17
US20040186127A1 (en) 2004-09-23
RU2004124054A (ru) 2005-04-10
NZ533958A (en) 2007-09-28
EP1707566A1 (en) 2006-10-04
US20080103137A1 (en) 2008-05-01
CY1106138T1 (el) 2011-06-08
US8691814B2 (en) 2014-04-08
DE60305446T4 (de) 2009-07-09
DE60305446D1 (de) 2006-06-29
EP1474425B1 (en) 2006-05-24
RU2380368C2 (ru) 2010-01-27
DK1474425T3 (da) 2006-09-25
AU2003235741B2 (en) 2008-12-04
AU2003235741B8 (en) 2009-01-15
KR100980163B1 (ko) 2010-09-03
CN100503608C (zh) 2009-06-24
US20110105427A1 (en) 2011-05-05
AU2009200689A1 (en) 2009-03-12
NO20043290D0 (no) 2004-08-06
US7314936B2 (en) 2008-01-01
ES2262996T3 (es) 2006-12-01
JP4411455B2 (ja) 2010-02-10
NZ555911A (en) 2008-07-31
IL162884A0 (en) 2005-11-20
JP2005524621A (ja) 2005-08-18
SI1474425T1 (sl) 2006-10-31
AU2003235741A1 (en) 2003-07-24
MXPA04006614A (es) 2004-10-04
KR20040077707A (ko) 2004-09-06
CA2472479A1 (en) 2003-07-17
CA2472479C (en) 2011-10-11
PT1474425E (pt) 2006-09-29
NO20043290L (no) 2004-09-22
EP1474425A1 (en) 2004-11-10
CN1630657A (zh) 2005-06-22
DE60305446T2 (de) 2007-03-08
NO329994B1 (no) 2011-02-07

Similar Documents

Publication Publication Date Title
ZA200406272B (en) Deazapurines and uses thereof
US6277854B1 (en) Tricyclic antitumor farnesyl protein transferase inhibitors
DE69731544T2 (de) Trizyklische antitumor verbindungen mit farnesyl protein transferase inhibierender wirkung
US5231101A (en) Benzo[5,6]cyclohepta[1,2-B]pyridine derivatives and antiallergic agents comprising same
TWI236477B (en) beta-carboline compounds which bind to somatostatin receptors and block sodium channels
TW202144338A (zh) 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
CA3230542A1 (en) Novel ras inhibitors
EP4385989A1 (en) Sulfonamide derivative, preparation method therefor and medical use thereof
PT1542678E (pt) Derivados de 1h-1,2,4-triazol-3-carboxamida como ligandos de receptor de canabinóide-cb1
US6291470B1 (en) Indole derivatives process for producing the same and medicinal uses of the same
KR102834472B1 (ko) 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
WO2000044216A2 (en) Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
CN111574534B (zh) 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
CN110317202B (zh) 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
US6277850B1 (en) Pyrrolyl quinoxalindiones their production and use as AMPA receptor antagonists
WO2005077920A1 (en) Quinoxaline compounds and methods of using them
RS55362B1 (sr) Jedinjenje benzazepina
WO1994025466A1 (en) Water soluble derivatives of camptothecin and their use as antitumor agents
US6458792B1 (en) Compounds
RU2154066C2 (ru) Бензотиопираноиндазолы, фармацевтическая композиция на их основе и способ лечения опухоли
CN118638177A (zh) 杂环类化合物、其制备方法及其在医药上的应用
JP2008528552A (ja) 新規のインドロピリジン、ベンゾフラノピリジン及びベンゾチエノピリジン
WO2004063336A2 (en) Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis
CN114456173A (zh) 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用
KR20250069999A (ko) Tyk2 억제제로서의 치환된 피리다진-3-카르복스아미드 화합물